China Regenerative Medicine International Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was HKD 11.97 million compared to HKD 76.89 million a year ago. Net loss was HKD 6.09 million compared to net income of HKD 8.33 million a year ago. Basic loss per share from continuing operations was HKD 0.0213 compared to basic earnings per share from continuing operations of HKD 0.0292 a year ago.
For the nine months, sales was HKD 112.06 million compared to HKD 163.14 million a year ago. Net income was HKD 6.68 million compared to HKD 10.56 million a year ago. Basic earnings per share from continuing operations was HKD 0.0234 compared to HKD 0.037 a year ago.